natgillin/translations-raw huggingface dataset:
FeLV recombinant canarypox virus (vCP97)...................................................................  107.2 CCID50.
FeLV rekombiniran s virusom boginja kanarinca (vCP97) ..............................................  107,2 CCID50
Female
žene
Female
ženski
Female (72%) and male (28%) patients with a mean age of 59 years (range 18 – 95 years) were included.
Ispitivanje je uključivalo ženske (72%) i muške (28%) bolesnike srednje dobi od 59 godina (u rasponu od 18 do 95 godina).
Female 2169 0.77 [0.67;0.89] 0.65
Žene 2169 0,77 [0,67;0,89] 0,65
Female and male patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counseled regarding pregnancy prevention and planning.
Žene i muškarce reproduktivne dobi mora se na početku liječenja upozoriti na povećan rizik od gubitka ploda i kongenitalnih malformacija te ih se mora savjetovati o sprječavanju i planiranju trudnoće.
Female and male patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counseled regarding pregnancy prevention, and planning.
Žene i muškarce reproduktivne dobi mora se na početku liječenja upozoriti na povećan rizik od gubitka ploda i kongenitalnih malformacija te ih se mora savjetovati o sprječavanju i planiranju trudnoće.
Female and male patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counselled regarding pregnancy prevention and planning.
Žene i muškarce reproduktivne dobi mora se na početku liječenja upozoriti na povećan rizik od gubitka ploda i kongenitalnih malformacija te ih se mora savjetovati o sprječavanju i planiranju trudnoće.
Female and male patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counselled regarding pregnancy prevention, and planning.
Žene i muškarce reproduktivne dobi mora se na početku liječenja upozoriti na povećan rizik od gubitka ploda i kongenitalnih malformacija te ih se mora savjetovati o sprječavanju i planiranju trudnoće.
Female and male patients of reproductive potential should be made aware of the risks and follow the recommendations provided in section 4.6 (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with mycophenolate.
Žene i muškarce reproduktivne dobi mora se upoznati s rizicima i upozoriti da se pridržavaju preporuka navedenih u dijelu 4.6 (npr. korištenja kontracepcijskih metoda, provođenja testova na trudnoću) prije, tijekom i nakon liječenja mikofenolatom.
Female and male patients of reproductive potential should be made aware of the risks and follow the recommendations provided in section 4.6. (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with CellCept.
Žene i muškarce reproduktivne dobi mora se upoznati s rizicima i upozoriti da se pridržavaju preporuka navedenih u dijelu 4.6 (npr. korištenja kontracepcijskih metoda, provođenja testova na trudnoću) prije, tijekom i nakon liječenja lijekom CellCept.
Female and male patients of reproductive potential should be made aware of the risks and follow the recommendations provided in section 4.6. (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with Myclausen.
Žene i muškarce reproduktivne dobi mora se upoznati s rizicima i upozoriti da se pridržavaju preporuka navedenih u dijelu 4.6 (npr. korištenja kontracepcijskih metoda, provođenja testova na trudnoću) prije, tijekom i nakon liječenja lijekom Myclausen.
Female fertility
Plodnost u žena
Female fertility is likely to be compromised during treatment with ramucirumab based on studies in animals (see section 5.3).
Na temelju istraživanja na životinjama, postoji vjerojatnost štetnog utjecaja liječenja ramucirumabom na plodnost žena (vidjeti dio 5.3).
Female gender
Ženski spol
Female gender and higher CD4 counts (>250/mm3 in adult females and >400/mm3 in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine.
Žene i bolesnici s povišenim brojem CD4 (> 250/mm3 u odraslih žena i >400/mm3 u odraslih muškaraca) imaju na početku terapije nevirapinom i povišeni rizik jetrenih nuspojava ako pri tome bolesnici imaju HIV-1 RNK u plazmi – tj. koncentraciju ≥50 kopija/ml.
Female gender, lower body weight, and underlying renal impairment
Ženski spol, niža tjelesna težina i postojeće oštećenje bubrega
Female mice receiving duloxetine for 2 years had an increased incidence of hepatocellular adenomas and carcinomas at the high dose only (144 mg/kg/day), but these were considered to be secondary to hepatic microsomal enzyme induction.
Ženki miševa koje su primale duloksetin tijekom 2 godine imale su povećanu incidenciju hepatocelularnih adenoma i karcinoma samo pri visokim dozama (144 mg/kg/dan), no to se smatralo sekundarnom posljedicom indukcije mikrosomalnih enzima jetre.
Female partners of male patients must have a routine pregnancy test performed monthly during treatment and for seven months thereafter (see section 4.6).
Žene čiji partneri uzimaju Ribavirin Teva Pharma B.V moraju provoditi rutinski test na trudnoću jedanput mjesečno za vrijeme liječenja partnera i tijekom 7 mjeseci nakon prestanka njegova liječenja (vidjeti dio 4.6).
Female patient of childbearing potential
za bolesnice u reproduktivnoj dobi
Female patient of childbearing potential
za ženske bolesnike u reproduktivnoj dobi
Female patient of non-childbearing potential
za ženske bolesnike koji nemaju reproduktivni potencijal
Female patients
Bolesnice
Female patients had a 15% higher plasma exposure (AUCτ,ss, body weight corrected) than male patients.
Bolesnice su imale 15% veću izloženost u plazmi (AUCτ,ss, korigiran za tjelesnu težinu) nego muški bolesnici.
Female patients Male patients
Žene Muškarci
Female patients must have a routine pregnancy test performed monthly during treatment and for four months thereafter.
U bolesnica se moraju provoditi rutinski testovi na trudnoću jedanput mjesečno za vrijeme liječenja i tijekom 4 mjeseca nakon prestanka liječenja.
Female patients of childbearing age and their male partners
Bolesnice reproduktivne dobi i njihovi partneri
Female patients of childbearing potential and male patients with female partners of childbearing potential must use an effective form of contraception during treatment with ribavirin and after completion of ribavirin treatment for a duration as specified in the Summary of Product Characteristics for ribavirin.
Bolesnice reproduktivne dobi i muški bolesnici koji imaju partnerice reproduktivne dobi, moraju koristiti učinkovitu metodu kontracepcije tijekom liječenja ribavirinom i nakon završetka liječenja ribavirinom toliko dugo koliko je navedeno u sažetku opisa svojstava lijeka za ribavirin.
Female patients of childbearing potential have to use effective contraception and pregnant women should not use Eylea
Žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju i trudnice ne smiju koristiti lijek Eylea
Female patients of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinylestradiol and containing norgestimate as the progestagen or should use an alternative reliable method of contraception (see sections 4.5 and 4.6).
Bolesnice u reproduktivnoj dobi moraju primjenjivati hormonsku kontracepciju koja sadrži najmanje 30 µg etinilestradiola i norgestimat kao progestagen ili moraju primjenjivati drugu pouzdanu metodu kontracepcije (vidjeti dijelove 4.5 i 4.6).
Female patients should use adequate contraception as fertility may be increased.
Bolesnice moraju koristiti odgovarajuću kontracepciju, jer plodnost može biti povećana.
Female volunteers receiving repeated doses directly to the cervix and vagina of up to five times the recommended dose for the male partner, had maximum plasma levels of lidocaine which were less than 8% of toxic levels, and prilocaine which were less than 1% of toxic levels.
Žene koje su se javile dobrovoljno i primale više uzastopnih doza izravno na cerviks i vaginu u količini koja je odgovarala do peterostrukoj predviđenoj za muškog partnera imale su najveće zabilježene razine lidokaina u plazmi manje od 8 %, dok su imale razinu prilokaina u plazmi manju od 1 % toksične razine.
females
muškaraca i žena
females
Systemic
Females of child-bearing age should take the necessary precautions to avoid pregnancy for 1 month, or according to doctor’s recommendation, after they have been given the vaccine.
Žene reproduktivne dobi moraju primijeniti odgovarajuće mjere opreza kako bi izbjegle trudnoću tijekom razdoblja od 1 mjeseca nakon cijepljenja ili prema preporuci liječnika.
femoral
frakture femura
femoral fractures†
dijafizealne
femoral fractures†
frakture
femoral fractures†
frakture femura
Femoral neck BMD
BMD vrata bedrene kosti
Fenbendazole
Fenbendazol
Fenbendazole 200 mg
Fenbendazol 200 mg
Fenbendazole has an ovicidal effect on nematode eggs.
Panacur AquaSol ima ovicidalni učinak na jaja nematoda.
Fendrix contains two things called “MPL” (a non-toxic purified fat derivative from bacteria) and “aluminium phosphate”.
Fendrix sadrži dvije tvari koje nazivamo “MPL” (netoksični, pročišćeni derivat masti iz bakterije) i "aluminij fosfat".
Fendrix helps your body to produce its own protection against the virus (antibodies).
Fendrix pomaže Vašem tijelu kako bi ono samo razvilo zaštitu protiv virusa (antitijela).
Fendrix is a vaccine which prevents hepatitis B. It is used for patients with kidney problems:
Fendrix je cjepivo koje sprječava hepatitis B. Koristi se kod bolesnika s bubrežnim smetnjama:
Fendrix is a white, milky suspension presented in a glass prefilled syringe (0.5 ml).
Fendrix je bijela, mliječna suspenzija u staklenoj, prethodno napunjenoj štrcaljki (0.5 ml).
Fendrix is available in packs of 1 (with or without a separate needle) and in a pack size of 10 without needles.
Fendrix je dostupan u pakiranjima po 1 kom (sa ili bez odvojene igle) i u pakiranjima po 10 kom bez igala.
Fendrix may not protect you from being ill if you have already caught the hepatitis B virus.
Fendrix Vas možda neće zaštititi ako ste već bili izloženi virusu hepatitisa B.
Fendrix should be injected intramuscularly in the deltoid region.
Fendrix se treba davati kao intramuskularna injekcija u deltoidno područje.
Fendrix suspension for injection
Fendrix suspenzija za injekciju
Fendrix suspension for injection IM
Fendrix suspenzija za injekciju i.m.
fenfluramine (to reduce weight) tritoqualine (to treat allergies)
fenfluramin (za smanjenje tjelesne težine) tritokvalin (za liječenje alergija)
Fenian Street Dublin 2, Ireland
Palmerston House Fenian Street Dublin 2, Irska
Feno 145 +
feno 145 + simva 40
Fenofibrate and simvastatin are not CYP 3A4 inhibitors or inducers.
Fenofibrat i simvastatin nisu inhibitori ni induktori CYP 3A4.
Fenofibrate and simvastatin are not inhibitors of CYP 2D6, CYP 2E1, or CYP 1A2.
Fenofibrat i simvastatin nisu inhibitori CYP 2D6, CYP 2E1 ili CYP 1A2.
Fenofibrate is a mild to moderate inhibitor of CYP 2C9 and a weak inhibitor of CYP 2C19 and CYP 2A6.
Fenofibrat je blagi do umjeren inhibitor CYP 2C9 i slabi inhibitor CYP 2C19 i CYP 2A6.
Fenofibrate is a ‘PPAR agonist’.
Fenofibrat je „agonist PPAR“.
Fenofibric acid is strongly bound to plasma albumin (more than 99%).
Fenofibrična kiselina snažno se veže na albumine plazme (više od 99%).
Fentanyl
ketokonazola i
Fentanyl (5 μg/kg single dose)
se prepoloviti dozu omeprazola.
Fentanyl (5 g/kg single dose)
Treba razmotriti smanjenje doze statina.
Fentanyl 50 mg/ml
Fentanil 50 mg/ml
Fentanyl AUC0-∞  1.34-fold
Fentanil AUC  1,34 puta
Fentanyl can pass into the breast milk and may cause side effects to the breast-fed child.
Fentanil može prijeći u majčino mlijeko i prouzročiti nuspojave u dojenčeta.
Fentanyl citrate concentrations obtained in serum were higher than in plasma: Serum AUC and Cmax were approximately 20% and 30% higher than plasma AUC and Cmax, respectively.
Koncentracije fentanil citrata dobivene u serumu bile su više nego u plazmi: Serumske vrijednosti AUC i Cmax bile su približno 20% i 30% više od plazmatskih vrijednosti AUC i Cmax.
Fentanyl gradually moves through the skin into your dog’s bloodstream and then relieves pain.
Fentanil postepeno preko kože prodire u krvotok, nakon čega smanjuje bol.
Fentanyl is absorbed quickly through the lining of your nose and into the blood stream.
Fentanil se brzo apsorbira kroz unutrašnju sluznicu nosa i zatim u optok krvi.
Fentanyl is an opioid analgesic, interacting predominantly with the opioid µ-receptor.
Fentanil je opioidni analgetik koji pretežno stupa u interakcije s opioidnim µ-receptorom.
Fentanyl is highly lipophilic and is well distributed beyond the vascular system, with a large apparent volume of distribution.
Fentanil je visoko lipofilan lijek te se dobro raspodjeljuje izvan krvožilnog sustava s velikim očitim volumenom raspodjele.
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when Effentora is given concurrently with agents that affect CYP3A4 activity.
Fentanil se metabolizira uglavnom preko sustava izoenzima humanog citokroma P450 3A4 (CYP3A4) pa se stoga mogu javiti interakcije kad se Effentora daje istovremeno s lijekovima koji utječu na aktivnost CYP3A4.
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when PecFent is given concurrently with medicinal products that affect CYP3A4 activity.
Fentanil se metabolizira uglavnom putem izoenzimskog sustava ljudskog citokroma P450 3A4 (CYP3A4), stoga do potencijalnih interakcija može doći kada se PecFent daje istodobno s lijekovima koji utječu na aktivnost CYP3A4.
Fentanyl is metabolised primarily in the liver via CYP3A4.
Fentanil se prvenstveno metabolizira u jetri putem CYP3A4.
Fentanyl may produce bradycardia or hypotension and should, therefore, be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
Fentanil može izazvati bradikardiju ili hipotenziju, zbog čega je potreban oprez u bolesnika s bradiaritmijama ili bilo kojom značajnom kardiovaskularnom bolešću.
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child.
Fentanil prelazi u majčino mlijeko i može uzrokovati sedaciju i respiratornu depresiju u dojenčadi.
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child.
Fentanil prelazi u majčino mlijeko i u dojenčeta može izazvati sedaciju i respiratornu depresiju.
Fentanyl Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of fentanyl.
Fentanil Ritonavir doziran kao farmakokinetički pojačivač ili kao antiretrovirusni lijek inhibira CYP3A4 te se stoga očekuje da će povećati koncentracije fentanila u plazmi.
Fentanyl should not be used by breastfeeding women and breast-feeding should not be restarted until at least 5 days after the last administration of fentanyl.
Žene koje doje ne smiju primjenjivati fentanil, a dojenje se ne smije ponovno započeti još najmanje 5 dana nakon zadnje primjene fentanila.
Fentanyl should not be used by breastfeeding women and breastfeeding should not be restarted until at least 5 days after the last administration of fentanyl.
Žene koje doje ne smiju koristiti fentanil te se dojenje ne smije nastaviti dok ne prođe barem 5 dana od zadnje primjene fentanila.
fentanyl – used to treat cancer pain
fentanil – koristi se za liječenje maligne boli
Fentanyl, alfentanil, methadone, buprenorphine/naloxone
Fentanil, alfentanil, metadon, buprenorfin/nalokson
Feraccru 30 mg hard capsules
Feraccru 30 mg tvrde kapsule
Feraccru 30 mg hard capsules Iron (as ferric maltol)
Feraccru 30 mg tvrde kapsule željezo (u obliku željezovog (III) maltolata)
Feraccru capsules should be taken whole on an empty stomach (with half a glass of water), as the absorption of iron is reduced when Feraccru is taken with food (see section 4.5).
Kapsule Feraccru trebaju se uzimati cijele i natašte (s pola čaše vode) jer je apsorpcija željeza smanjena kada se Feraccru uzima s hranom (vidjeti dio 4.5.).
Feraccru contains iron in a stable ferric state as a complex with a trimaltol ligand.
Feraccru sadrži željezo u stabilnom željeznom stanju kao kompleks s trimaltol ligandom.
Feraccru ferric maltol
Feraccru željezov (III) maltolat
Feraccru has been shown to be effective in increasing haemoglobin levels in patients with inflammatory bowel disease and iron deficiency anaemia.
Dokazana je učinkovitost lijeka Feraccru kad je riječ o povećanju razine hemoglobina u bolesnika s upalnom bolešću crijeva i anemijom zbog manjka željeza.
Feraccru has not been studied in patients with impaired renal and/or hepatic function.
Ferracru nije ispitivan u bolesnika s oštećenjem funkcije jetre i/ili bubrega.
Feraccru is a red hard capsule containing a reddish-brown powder.
Feraccru je crvena tvrda kapsula koja sadrži crvenkasto-smeđi prah.
Feraccru is an iron-containing medicine.
Feraccru je lijek koji sadrži željezo.
Feraccru is indicated in adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD) (see section 5.1).
Feraccru je indiciran u odraslih za liječenje anemije zbog manjka željeza (IDA, engl.: iron deficiency anaemia) u bolesnika koji boluju od upalne bolesti crijeva (IBD, engl.: inflammatory bowel disease) (vidjeti dio 5.1.).
Feraccru is unlikely to have any effect on the ability to drive and use machines.
Nije vjerojatno da Feraccru utječe na sposobnost upravljanja vozilima i strojevima.
Feraccru is used in adults with inflammatory bowel disease (IBD) to treat low iron stores in your body.
Feraccru se upotrebljava u odraslih s upalnom bolešću crijeva (IBD, engl. inflammatory bowel disease) radi liječenja niske razine željeza u tijelu.
Feraccru must not be administrated to children (see section 4.2).
Feraccru se ne smije davati djeci (vidjeti dio 4.2.).
Feraccru should not be used in patients with inflammatory bowel disease (IBD) flare or in IBD- patients with haemoglobin (Hb) <9.5 g/dl.
Feraccru se ne smije koristiti u bolesnika s akutnom upalnom bolešću crijeva (IBD) ili u bolesnika s
Feraccru was compared with placebo (a dummy treatment) in one main study involving 128 patients with inflammatory bowel disease who had iron deficiency anaemia, defined as haemoglobin levels below 12.0 grams per decilitre (g/dl).
Lijek Feraccru uspoređen je s placebom (slijepo liječenje) u jednom glavnom ispitivanju koje je provedeno na 128 bolesnika s upalnom bolešću crijeva, a koji su imali anemiju zbog manjka željeza s razinama hemoglobina ispod 12,0 grama po decilitru (g/dl).
Feraccru was more effective than placebo at increasing haemoglobin levels: in patients taking Feraccru, haemoglobin levels increased on average from 11.0 to 13.2 g/dl whereas in patients given placebo they remained around 11.1 g/dl.
Lijek Feraccru bio je učinkovitiji od placeba u povećanju razina hemoglobina: u bolesnika koji su uzimali Feraccru, razine hemoglobina prosječno su porasle s 11,0 na 13,2 g/dl, dok su u bolesnika koji su uzimali placebo razine ostale otprilike 11,1 g/dl.
Fermentation: Eli Lilly and Company, Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, USA
Fermentacija: Eli Lilly and Company, Lilly Technology Center Building 333 and 324, Indianapolis, Indiana, SAD
Ferrer Internacional, S.A. Spain
Ferrer Internacional, S.A. Španjolska
Ferrets
Afrički tvor
Ferrets
Afrički tvorovi:
Ferrets in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms.
Afrički tvorovi koji žive u područjima gdje je enzootski proširena dirofilarioza ili oni koji su putovali u takva područja, mogu biti invadirani odraslim srčanim crvom.
Ferrets were vaccinated on days 0 and 21 and challenged by the intra-tracheal route on day 49 with a lethal dose of either H5N1/A/Vietnam/1194/04 or heterologous H5N1/A/Indonesia/5/05.
Tvorovi su cijepljeni na 0. i 21. dan, a 49. dana intratrahealnim putem opterećeni su letalnom dozom H5N1/A/Vietnam/1194/04 ili heterolognog H5N1/A/Indonesia/5/05.
Ferrets were vaccinated on days 0 and 21 and challenged by the intra-tracheal route on day 49 with a lethal dose of either H5N1/A/Vietnam/1194/04 or heterologous H5N1/A/Indonesia/5/05.
Tvorovi su cijepljeni na nulti i 21. dan, a 49. dana intratrahealnim putem opterećeni su letalnom dozom H5N1/A/Vietnam/1194/04 ili heterolognim H5N1/A/Indonesia/5/05.
Ferrets:
Afrički tvor:
Ferrets:
Afrički tvorovi:
Ferrets: There is no information available in ferrets.
Afrički tvor:; Nema dostupnih informacija
Ferric maltol is not systemically available.
Željezov (III) maltolat -maltol nije sistemski dostupan.
Ferric oxide, black (E172) Fycompa 10 mg film-coated tablets
Fycompa 10 mg filmom obložene tablete
Ferring Ελλάς MEΠΕ Τηλ: +30 210 68 43 449
Ferring Ελλάς MEΠΕ
Ferriprox 100 mg/ml oral solution
Ferriprox 100 mg/ml oralna otopina
Ferriprox 100 mg/ml oral solution Deferiprone
Ferriprox 100 mg/ml oralna otopina deferipron
Ferriprox 1000 mg film-coated tablets 3 years.
Ferriprox 1000 mg filmom obložene tablete 3 godine.
Ferriprox 1000 mg film-coated tablets Do not store above 30ºC.
Ferriprox 1000 mg filmom obložene tablete Ne čuvati na temperaturi iznad 30 °C.
Ferriprox 1000 mg tablets are white to off-white, capsule-shaped, film-coated tablets imprinted “APO” bisect “1000” on one side, plain on the other.
Tablete Ferriprox od 1000 mg su bijele do gotovo bijele filmom obložene tablete oblika kapsule, s otisnutom oznakom „APO“ s jedne strane razdjelne crte i „1000“ s druge na jednoj strani tablete, te bez oznaka s druge strane.
Ferriprox 500 mg film-coated tablets 5 years.
Ferriprox 500 mg filmom obložene tablete 5 godina.
Ferriprox 500 mg film-coated tablets Do not store above 30ºC.
Ferriprox 500 mg filmom obložene tablete Ne čuvati na temperaturi iznad 30 °C.
Ferriprox 500 mg film-coated tablets Each tablet contains 500 mg deferiprone.
Ferriprox 500 mg filmom obložene tablete Svaka tableta sadrži 500 mg deferiprona.
Ferriprox 500 mg film-coated tablets EU/1/99/108/001
Ferriprox 500 mg filmom obložene tablete EU/1/99/108/001
Ferriprox 500 mg film-coated tablets Ferriprox 1000 mg film-coated tablets
Ferriprox 500 mg filmom obložene tablete Ferriprox 1000 mg filmom obložene tablete
Ferriprox can be taken with or without food however, you may find it easier to remember to take Ferriprox if you take it with your meals.
Ferriprox se može uzimati s hranom ili bez jela; možda će vam ipak biti lakše upamtiti da uzmete Ferriprox ako ga uzimate s obrocima.
Ferriprox deferiprone
Ferriprox deferipron
Ferriprox is a medicine that contains the active substance deferiprone.
Ferriprox je lijek koji sadrži djelatnu tvar deferipron.
Ferriprox is a medicine that removes iron from the body.
Ferriprox je lijek koji uklanja željezo iz tijela.
Ferriprox is an ‘iron chelator’ (a substance that attaches to iron) that is used to treat iron overload (an excess of iron in the body) in patients with thalassaemia major.
Ferriprox je „kelator željeza” (tvar koja se veže na željezo), a koristi se za liječenje preopterećenja željezom (višak željeza u tijelu) u bolesnika s talasemijom major.
Ferriprox is packaged in bottles of 50 tablets, bottles of 100 tablets, and blister packs of 50 tablets.
Ferriprox je pakiran u bocama od 50 tableta, bocama od 100 tableta i blister pakiranjima od 50 tableta.
Ferriprox must also not be used with medicines that might cause neutropenia or agranulocytosis.
Lijek Ferriprox također se ne smije primjenjivati zajedno s lijekovima koji mogu izazvati neutropeniju ili agranulocitozu.